Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies.

Abundio BalgosSuad HannawiWen-Li ChenAlaa AbuqutaLinda SafeldinAala HassanAhmad AlamadiLouie TiradorAnjuli May JaenRalph Elvi VillalobosChen MoZi-Jing YueYing MaQing-Shuang WangRen-Du WenZheng YaoJia-Ping YuWen-Rong YaoJian-Hui ZhangKun-Xue HongYong LiuJing-Xin Li

Published in: Expert review of vaccines (2024)

Study-1, www.clinicaltrials.gov, identifier is NCT05323435; Study-2, www.clinicaltrials.gov, identifier is NCT05084989.

Keyphrases

sars cov
clinical trial
open label
double blind
study protocol
coronavirus disease